Wells Fargo & Company Forecasts Strong Price Appreciation for American Well (NYSE:AMWL) Stock

American Well (NYSE:AMWL) had its price target upped by research analysts at Wells Fargo & Company from $16.00 to $18.00 in a research note issued on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price would indicate a potential upside of 31.49% from the stock’s previous close.

Several other research firms have also commented on AMWL. Stifel Nicolaus lifted their price target on American Well from $11.00 to $12.00 and gave the stock a “hold” rating in a report on Wednesday. Truist Financial set a $12.00 price objective on shares of American Well and gave the company a “hold” rating in a report on Thursday, August 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of American Well in a report on Thursday, October 15th. Finally, Needham & Company LLC restated a “hold” rating on shares of American Well in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, American Well has an average rating of “Hold” and an average target price of $11.30.

American Well Price Performance

Shares of NYSE:AMWL traded up $0.95 during midday trading on Wednesday, hitting $13.69. The company had a trading volume of 65,267 shares, compared to its average volume of 100,865. American Well has a twelve month low of $3.71 and a twelve month high of $15.16. The stock has a market cap of $226.55 million, a price-to-earnings ratio of -2.84 and a beta of 1.72. The business’s 50-day simple moving average is $12.95 and its 200-day simple moving average is $8.99.

American Well (NYSE:AMWL) last released its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.67) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.11. The company had revenue of $48.99 million for the quarter, compared to analyst estimates of $47.28 million. American Well had a negative return on equity of 30.12% and a negative net margin of 35.75%. As a group, sell-side analysts forecast that American Well will post -2.56 EPS for the current year.

Insider Buying and Selling

In other American Well news, insider Phyllis Gotlib sold 6,677 shares of the firm’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $13.00, for a total transaction of $86,801.00. Following the completion of the sale, the insider owned 142,504 shares of the company’s stock, valued at $1,852,552. This trade represents a 4.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Dmitry Zamansky sold 8,442 shares of the firm’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $13.00, for a total value of $109,746.00. Following the sale, the insider directly owned 224,178 shares of the company’s stock, valued at approximately $2,914,314. This trade represents a 3.63% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 19,457 shares of company stock worth $248,519 over the last quarter. 12.84% of the stock is currently owned by insiders.

Hedge Funds Weigh In On American Well

An institutional investor recently bought a new stake in American Well stock. Candriam S.C.A. purchased a new position in shares of American Well Corporation (NYSE:AMWL) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 10,441 shares of the company’s stock, valued at approximately $142,000. Candriam S.C.A. owned 0.06% of American Well at the end of the most recent quarter. Institutional investors own 56.05% of the company’s stock.

Key Headlines Impacting American Well

Here are the key news stories impacting American Well this week:

• Positive Sentiment: Third-quarter revenue was $48.99 million, above the cited $47.28 million estimate. The loss of $0.67 per share also narrowed from $1.74 a year earlier, and beat the $0.78 loss estimate cited by MarketBeat. Amwell Q3 2026 results
• Neutral Sentiment: Stifel Nicolaus lifted its price target from $11 to $12 but kept a Hold rating. The higher target is a modest positive, though it was still about 9.3% below the $13.24 share price referenced in the report. Stifel Nicolaus rating information
• Negative Sentiment: Consensus comparisons varied: Zacks said the $0.67 quarterly loss per share was slightly wider than its $0.66 estimate. The company also remains loss-making, a continuing risk for investors. Zacks Q3 earnings coverage

About American Well

American Well, doing business as Amwell, is a digital healthcare company that provides technology and services for virtual care. Its platform connects patients with healthcare professionals through video and other digital channels, supporting services such as urgent care, behavioral health, primary care and specialty consultations.

Amwell primarily serves health systems, health plans, employers and other healthcare organizations. Its offerings include the Amwell Converge platform, which is designed to help organizations develop, manage and integrate digital care programs with existing clinical workflows and healthcare systems.

Founded in 2006 by brothers Ido and Roy Schoenberg, the company was formerly known as American Well and adopted the Amwell brand in 2020.